One of the major causes of interindividual variation of drug effects is genetic variation of drug metabolism. Genetic polymorphisms of drug-metabolizing enzymes give rise to distinct subgroups in the population that differ in their ability to perform certain drug biotransformation reactions. Polymorphisms are generated by mutations in the genes for these enzymes, which cause decreased, increased, or absent enzyme expression or activity by multiple molecular mechanisms. Moreover, the variant alleles exist in the population at relatively high frequency. Genetic polymorphisms have been described for most drug metabolizing enzymes. The molecular mechanisms of three polymorphisms are reviewed here.
INTRODUCTION
The term genetic polymorphism defines monogenic traits that exist in the normal population in at least two phenotypes, neither of which is rare (1, 2). Genetic polymorphisms in drug metabolism are common occurrences. Mutations in the genes for numerous drug-metabolizing enzymes cause enzyme variants with higher or lower activity or lead to the partial or total absence of an enzyme protein.
Genetic polymorphisms have been described for a wide variety of drug and xenobiotic metabolizing enzymes. Many of these variations were first identified by the occurrence of adverse reactions after normal doses of drugs in patients or volunteers. The association between decreased drug clearance and decreased activity of a drug-metabolizing enzyme, the inherited nature of the deficiency, and its frequency and clinical importance was then evaluated. Phenotyping methods involving administration of probe drugs and measurement of metabolites in body fluids or determination of enzyme activity in families and populations were used for this purpose. During the past 10 years, several of these polymorphisms have been studied at the protein and gene level, and simple DNA tests have been developed to predict the phenotype.
In this review, we summarize studies in our laboratory and in others of the molecular mechanisms of three genetic polymorphisms, the acetylation (or NAT2) polymorphism, the debrisoquine (or CYP2D6) polymorphism, and the mephenytoin (or CYP2C19) polymorphism. We restrict our review to these polymorphisms because their occurrence in different large populations is well established, they involve clinically important drugs, and they represent the best studied examples of these variations in regard to mutations of the genes and their functional and clinical consequences.
In addition to the three polymorphisms described here, genetic polymorphisms are known for several other human cytochrome P450 genes that code for drug-metabolizing enzymes, including CYP1A1, CYP2A6, CYP2C9, CYP2E1, and for a number of conjugating enzymes, such as glutathion S-transferases, methyl-transferases, and sulfotransferases. However, the importance of these polymorphisms for clinically used drugs is less obvious at this time, or their genes have not been studied in detail yet. Recent reviews and books have been published that cover various aspects of genetic polymorphisms and their clinical or toxicologic relevance (3-11). Because of space limitations, we sometimes refer to these reviews, rather than citing original articles.
THE N-ACETYLTRANSFERASE POLYMORPHISM

Discovery and Clinical Relevance
Variability in drug acetylation was discovered nearly 40 years ago when the fate of isoniazid was studied in patients who had tuberculosis. Marked interindividual variation in the elimination of isoniazid was first described in 1953 by Bönicke & Reif (12) . Family studies revealed that this variation was genetically controlled and that "slow acetylators" of isoniazid were homozygous for a recessive gene, whereas "rapid acetylators" were either homozygous or heterozygous for the normal or wild-type gene. In the following years, a number of sulfonamides (sulfadiazine, sulfamethazine, sulfapyridine, sulfameridine, and sulfadoxine), numerous other drugs (aminoglutethimide, amonafide, amrinone, dapsone, dipyrone, endralazine, hydralazine, isoniazid, prizidilol, and procainamide), and metabolites of clonazepam and caffeine were discovered to be polymorphically acetylated. Recent reviews have discussed the acetylation polymorphism (6, [13] [14] [15] [16] [17] [18] .
The proportions of rapid and slow acetylator phenotypes vary remarkably in populations of different ethnic or geographic origin. Most populations in Europe and North America have 40 to 70% slow acetylators, whereas populations along the Pacific Asian littoral (e.g. Japanese, Chinese, Korean, and Thai) have only 10 to 30% slow acetylators. The molecular aspect of interethnic and geographic variation of the acetylation polymorphism is discussed later in this review.
The association of the acetylation polymorphism with drug toxicity, such as sulfonamide hypersensitivity reactions (19) , and its role as a risk factor for certain diseases, in particular bladder cancer, has received much attention and has been extensively studied (6, 13, (20) (21) (22) . A discussion of these associations and their presumed mechanisms is beyond the scope of this review.
Molecular Mechanism
STUDIES IN HUMAN LIVER Early studies clearly established that the observed variation in acetylation of isoniazid was caused by a difference in the activity of a cytosolic N-acetyltransferase in the liver that involved transfer of acetate from acetyl coenzyme A (CoASAc) to the substrate (CoASAc; NAT, EC2.3.1.5) Some arylamines, such as p-aminobenzoate and (PABA) and p-aminosalicylate (PAS), are equally well acetylated by rapid and slow acetylators and therefore were called "monomorphic" in contrast to the "polymorphic" substrates isoniazid, sulfamethazine, and others (13, 23) . Jenne (24) performed the first detailed biochemical study of drug acetylation in liver tissue of rapid and slow acetylators and suggested that two different enzymes were responsible for the metabolism of monomorphic and polymorphic arylamines, one being quantitatively decreased in livers of slow acetylators.
Major progress in the purification of a human liver acetyltransferase that can acetylate the substrate sulfamethazine and the development of polyclonal antibodies that recognize this protein was achieved in 1989 (25) . In liver biopsy specimens from surgical patients who had been phenotyped with the use of the caffeine test, slow acetylation was associated with markedly reduced but still detectable levels of immunoreactive NAT protein (26) , which suggests a quantitative rather than a qualitative difference of the human enzyme protein, and confirms the initial proposal of Jenne (24) . Subsequent studies (23) revealed that an early unstable peak of NAT-activity on anion-exchange chromatography with low affinity for sulfamethazine, but high affinity for the monomorphic substrates PABA and PAS, had been overlooked. This fraction corresponds to what we now recognize as the distinct but related enzyme NAT1, whereas the initially purified protein (25) corresponds to the polymorphic NAT2.
In New Zealand white rapid acetylator rabbits, NAT protein and its mRNA are more abundant. This finding allowed Andres et al (27) to prepare a highly purified enzyme. Information from peptide sequences of this enzyme were used by Blum et al (28) to synthesize an oligonucleotide probe and, in combination with antibodies prepared against purified rabbit NAT, to clone a rabbit cDNA encoding an enzyme with high specific activity for sulfamethazine acetylation. Immunochemical studies suggested complete absence of this protein in slow acetylator rabbits, in contrast to the only partial reduction of NAT2 protein in livers of human slow acetylators. The absence of the NAT protein in slow acetylator rabbits has now been explained by a gene deletion mechanism (28) .
N-ACETYLTRANSFERASE GENES NAT1 AND NAT2 Human genes for acetyltransferases were cloned by Blum et al (29) , who used the rabbit cDNA probe from genomic DNA of an obligate heterozygous rapid acetylator individual identified by a pedigree phenotyping study. The recombinant clones define three different, but closely related, human NAT genes: NAT1, NAT2, and the pseudogene NATP. According to a recently proposed nomenclature, NAT1 corresponds to NAT1 * 3, and NAT2 corresponds to NAT2 * 4 (18) . The product of the NAT2 (NAT2 * 4) gene expressed in COS cells showed protein immunoreactivity and kinetic properties identical to those of human NAT2 (NAT2 * 4) (23, 26, 29) , whose content in human liver varies with the acetylator phenotype. This established the NAT2 locus as the site of the classic human acetylation polymorphism. The NAT1 (NAT1 * 3) gene gives rise to a NAT protein with different electrophoretic and kinetic properties. This protein corresponds to the monomorphic NAT1 (NAT1 3) enzyme with high affinity for substrates such as PABA and PAS (23) .
Each of the two genes NAT1 and NAT2 has a single, intronless protein-coding exon with an open reading frame of 870 bp that produces a 290 amino acid (33-34 kDa) protein. Whereas the NAT1 gene produces its entire transcript from a single exon, the NAT2 mRNA is derived from both the protein-coding exon and a second, untranslated exon of 100 bp that is located about 8 kb upstream of the translation start site (29) (30) . The nucleotide homology between NAT1 and NAT2 is 87% in the coding region. There are only 55 amino acid differences, only 28 of which are nonconservative changes. The homologies to the rabbit cDNA rnat are 82% for both NAT1 and NAT2 (29) . The pseudogene NATP has high sequence homology to NAT1 and NAT2 (79%) but contains multiple frameshifts and stop codons. NAT1 and NAT2 were mapped to chromosome 8p21.3-23.1 (29, 31) .
The discovery of 2 separate genes that encode NAT1 and NAT2 has resolved the old question of monomorphic and polymorphic substrates (23) . Although NAT2 and NAT1 also have overlapping arylamine substrate specificities, e.g. for 2-aminofluorene and sulfomethoxazole (32), they also have unique activities. Only NAT1 can metabolize PABA and the folate catabolite paminobenzoyl-glutamate (33, 34) . There is a conserved cysteine residue across all vertebrate NATs that corresponds to cysteine 68 (18, 35, 36) , whereas the different substrate specificity between NAT1 and NAT2 seems to be related to differences in the C-terminal portion. Recent studies suggest that NAT1 function also may be genetically variable in human populations (see below).
GENETIC VARIABILITY OF NAT2 At the protein level, the slow acetylator phenotype is associated with a reduction of 10 to 20% of the quantity of NAT2 in liver cytosol (26) , whereas the mRNA content remains unchanged (37) . Several "decreased function alleles" of NAT2 have been identified that cause this decrease in NAT2 protein and, consequently, the recessively inherited slow acetylator phenotype (37-41) reviewed by Vatsis et al (18) .
Decreased function alleles Mutant alleles of NAT2 were first identified by restriction fragment analysis of genomic DNA samples from healthy individuals whose acetylator phenotype had been established by caffeine phenotyping (37) or isoniazid (42) and of DNA from human liver samples with known NAT2 enzyme activity (37) . Restriction fragment length polymorphisms (RFLPs) with NAT2 probes generated by Mspl, Kpnl, and Bam HI segregated with acetylator phenotype and defined three mutant alleles of NAT2, initially called M1, M2, and M3 (37) . To explore the molecular mechanism of slow acetylation, NAT2 genes were cloned from genomic libraries (37) or characterized as cDNAs (38) , and their sequence determined and compared with the wild-type gene sequence. The M1 allele had mutations at positions 341 and 481 (Tables 1 and 2 ), M2 at positions 282 and 590 (37) , and M3 at position 857 (38) . According to a recent nomenclature (18) , M1 corresponds to NAT2 * 5A, M2 to NAT2 * 6A, and M3 to NAT2 * 7A (Table 2) . Initially, only one mutation was reported at position 857 for NAT2 * 7A (38) . More recent studies now reveal two mutations in most if not all NAT * 7 alleles, one at position 857, and the other at position 282 (39) . These data were confirmed and extended by Vatsis et al (43) and by Hickman et al (40) , who sequenced amplified DNA from livers and lymphocytes of slow acetylators by using the sequence information of Blum et al (29) . Vatsis and coworkers (43) observed an allele with mutations at positions 341, 481, and 803 (NAT2
* 5B). Hickman and co-workers (40) observed an allele with mutations at positions 341 and 803 (NAT2 * 5C). Moreover, Bell et al (41) described a mutation at position 191 that occurs almost exclusively in blacks. The mutations of NAT2 and their functional consequences are summarized in Table 1 .
Of the seven point mutations in the coding region, five cause amino acid changes, and two are silent. Three mutations (G191A, C282T, and T341C), when present on both alleles (homozygosity), demonstrably cause the slow acetylator phenotype in vivo (41, 44) , whereas homozygous carriers of a single mutation A803G are rapid acetylators (45) . No homozygous carriers of mutations C418T, G590A, and G857A have been identified, even in large epidemiologic studies totaling more than 2000 DNA samples (44, (46) (47) (48) .
The common slow acetylator alleles carry multiple mutations, as summarized in Table 2 . The NAT2 * 5 A, B, C alleles share mutation T341C, whereas (44) (45) (46) (47) (48) , at least in whites. New point mutations (A434C, A845C) and additional alleles have been reported (40, 46, 48, 49) . The knowledge of practically all mutations of NAT2 that occur with frequencies of more than 0.1% and the information on their in vivo relevance in causing the slow acetylator phenotype has led to the development of genotyping tests of high efficiency and accuracy, either by allele-specific amplification by polymerase chain reaction (PCR), by restriction analysis, or ideally by a combination of the 2 procedures (37, 43-47, 49, 50) .
Functional characterization of mutant alleles
It is not entirely clear yet how these mutations cause a decreased amount of NAT2 protein in livers of slow acetylators. Initial studies in liver tissue (37) indicated that the genotype NAT2 * 5A/ * 5A and * 6A/ * 6A produce normal levels of NAT2 mRNA in the liver, whereas the quantity of NAT2 immunoreactive protein was markedly reduced or absent. None of these alleles appears to result in a total absence of NAT2 protein in the liver (26) . Expression of wild-type-variant chimeric genes in COS cells (37) or in CHO cells (51) , however, produced controversial results. In the study of Blum et al (37) , both mutations of * 5A were required. In the study of Abe et al (51) , however, the T341C mutation alone reduced enzyme protein.
The mutation G590A causing Arg197Glu in NAT2 * 6A and the mutation G857A causing Gly286Glu of NAT2 * 7B apparently result in proteins with reduced stability (37, 52) . Additional studies by Hein et al (52) with recombinant NAT2 allotypic variants expressed in Escherichia coli provide additional in vitro data. The expressed products of NAT2 * 5A, * 5B and * 5C had lower activities than * 6A and * 7B, whereas * 13 (C282T) had normal activity. Similarly, in vitro expressions in mammalian cell systems suggested normal activity of expressed recombinant NAT2 with C282T (37, 39, 52) . These in vitro results are in contrast to recent in vivo data from comparisons of caffeine metabolic ratios with genotypes by Cascorbi et al (44) . NAT2
* 13 was clearly a slow acetylator allele in homozygous carriers, and
* 5B had an apparently higher activity than * 6A. Thus, heterologous expression of NAT2 alleles in E. coli, COS, or CHO cells apparently does not consistently reflect the effects of mutations on stability or affinity for substrates of the protein in human liver (Table 1) (55) have provided evidence that NAT1 function is also widely variable in human populations. PAS acetylation (by urinary metabolic ratio) in 130 individuals was highly variable and suggested a bimodal distribution (56) . The comparison of sequences of NAT1 genes from 13 individuals revealed two variants: allele V 2 (NAT1 * 10), with two mutations in the 3 UTR, and allele V 3 (NAT1 * 11), with five point mutations and a nonanucleotide deletion in the 3 UTR. These alleles were present in 50% of the individuals and showed Mendelian inheritance in a small family. Sequence differences were also noted between the wild-type (V 1 ) allele and a previously published NAT1 sequence derived from a Japanese individual (38) .
The functional significance of these variants has not been tested. It is therefore not known whether the described variants are responsible for the apparent catalytic differences seen with NAT1 specific substrates. These recent findings, however, far from being resolved, put the term "monomorphic" for the NAT1 locus in question.
Interethnic Variability and Evolution
The frequency of the slow acetylator phenotype varies considerably among ethnic groups. Genotyping data of the common NAT2 alleles now allows us to trace the molecular history of the acetylation polymorphism (Table 3) . Two groups can be distinguished by the incidence of mutations T341C/C481T and G857A. Whites and Africans are very similar and have high frequencies of T341C/C481T (>28%) and low frequencies of G857A (≤5%). Japanese, Chinese, Korean, and other Asian populations have a low incidence of T341C/ C481T mutations (≤7%) and a higher incidence of G857A mutation (10 to 18%). The difference in the incidence of the slow acetylator phenotype be- tween Whites/Africans (40 to 70%) and Asian populations (10 to 30%) is thus mostly the result of the low incidence of the T341C/C481T alleles (NAT2 * 5A, B, C) in Asians. Amerindians appear to be similar to Asian populations regarding their high proportion of rapid acetylators and the T341C/C481T to G857A relationship (57) . Hispanics appear as intermediate between the White/African and the Asian groups (47, 48) . The data are consistent with the concept that the acetylation polymorphism has an ancient and common African origin, before spreading of human populations (58) . The practical absence of the NAT2 * 12 and * 14 alleles (A803G and G191A) in whites as compared with the >8% incidence of G191A in Africans suggests that these mutations occurred after the African/Non-African split ∼90,000 years ago.
THE DEBRISOQUINE-SPARTEINE POLYMORPHISM
Discovery and Clinical Relevance
In 1977, physicians at St. Mary's Hospital Medical School in London made the serendipitous observation that a volunteer's hypotensive response to debrisoquine, a sympatholytic antihypertensive drug, was markedly increased because of impaired metabolism (59) . At about the same time, a group of physicians in Bonn, Germany, independently observed increased side effects associated with decreased oxidative metabolism of sparteine, an alkaloid drug with antiarrhythmic actions (60) . Family studies revealed that both oxidative metabolic reactions are under monogenic control and that poor metabolizers are homozygous for a recessive allele. A simple test, the urinary metabolic ratio (MR), after administration of a probe drug can identify the extensive metabolizer (EM) and the poor metabolizer (PM) phenotype. This test, which has been applied to thousands of individuals, has documented that 5 to 10% of individuals in white populations are of the PM phenotype, compared with only 1 to 2% in Asian populations (6, 61).
The clinical importance of this polymorphism was initially questioned because the drugs leading to its discovery were soon either obsolete or of small distribution. It soon became known, however, that many other drugs are inefficiently metabolized in PM individuals. More than 40 clinically used drugs are now identified whose metabolism in vivo cosegregates with that of debrisoquine and sparteine. They include antiarrhythmics, such as N-propylajmaline, flecainide, propafenone, and mexiletine; antidepressants, such as amitriptyline, clomipramine, desipramine, fluoxetine, imipramine, maprotiline, mianserin, paroxetine, and nortriptyline; neuroleptics, such as haloperidol, perphenazine, and thioridazine; antianginals, such as perhexiline; opioids, such as dextrometorphan and codeine; and amphetamines, such as methamphetamine and methylenedioxymethamphetamine (ecstasy). Moreover, a large number of β-adrenergic receptor antagonists are influenced in their elimination by this polymorphism (6, 10, 62, 65, 66).
Numerous case reports and clinical studies have demonstrated that for some of these drugs, the polymorphic oxidation has therapeutic consequences, which lead either to a higher propensity to develop adverse reactions at conventional doses (as demonstrated by its discovery) or to decreased drug effects, e.g. absence of the analgesic effect of codeine in PMs (63) or therapeutic failure at normal antidepressant doses in ultrarapid metabolizers (64) . Moreover, epidemiologic studies have indicated that PMs and EMs may be at higher risk for certain diseases, including Parkinson's disease and some forms of cancer, although many of these associations are disputed. Detailed reviews of the clinical and toxicologic implications of the debrisoquine polymorphism have been published (4-6, 62, 65, 66).
Molecular Mechanism
STUDIES IN HUMAN LIVER The identification of the target P450 isozyme took several years of research by different groups, as has been reviewed in detail (67) . Early studies in human liver microsomes had suggested the deficiency of a minor P450 enzyme with debrisoquine 4-hydroxylase activity in the liver of PM individuals. However, purification of the respective P450 from human liver was extremely difficult, and antibodies obtained against these fractions were not specific enough to allow conclusions regarding the mechanism of deficient metabolism (68, 69) . With improved enzyme assays of high specificity and sensitivity, the deficient enzyme was characterized in liver biopsy specimens from donors who had known in vivo phenotype as a stereoselective (+)-bufuralol 1 -hydroxylase (70, 71) . Polyclonal antibodies against rat P450db1, which defined the 2D subfamily in rats (72) , were then shown to cross-react specifically with human CYP2D6, and the levels of CYP2D6 determined in a large collection of human liver specimens were highly correlated to bufuralol 1 -hydroxylase activity (71, 73) . The lack of immunoreactivity observed in several liver samples of PMs suggested absence of CYP2D6 protein as cause for the metabolic deficiency (71, 73) . This result was further confirmed with monoclonal antibodies (71, 74) and human LKM1 autoantibodies (75).
By using the polyclonal antibody against rat P450db1, a full length human cDNA was isolated. Sequence analysis revealed a distinct, novel member of the CYP2D subfamily (73) . In addition to the biochemical evidence, one other observation strongly suggested CYP2D6 as the target gene of the debrisoquinesparteine polymorphism. Eichelbaum and colleagues (76) found strong linkage of polymorphic sparteine oxidation to the P1 blood group, which had been mapped to the long arm of chromosome 22. The CYP2D locus (22q13.1) could subsequently be mapped by using the CYP2D6 cDNA (77, 78).
CYP2D GENES The CYP2D6 wild-type locus in human beings is comprised of the three highly homologous genes, CYP2D8P, CYP2D7P, and CYP2D6, which are located in this orientation (5 to 3 ) on a contiguous region of about 45 kb (79-81). Like other genes of the CYP2 family, CYP2D genes consist of nine exons and eight introns. CYP2D8P is a pseudogene that contains multiple deletions and insertions and causes a highly disrupted open reading frame (79, 81). The CYP2D7P gene is more similar to CYP2D6 than to CYP2D8P, and its coding sequence indicates only a single inactivating mutation, an insertion of T226 in the first exon. However, no specific mRNA product was detected in RNA from eight human livers, which indicates that it also is a pseudogene (79). Other sequenced CYP2D7 genes also contain the T226 mutation (81-83). Hence, CYP2D6 is the only CYP2D protein product in human beings, in contrast to rodents, which express most or all of their five functional CYP2D genes.
GENETIC VARIABILITY Basic information on the structural variability of the CYP2D6 locus was obtained in an extended RFLP analysis, in which 20 restriction enzymes were used to identify phenotype-associated polymorphisms in leukocyte DNA of PM and EM individuals and their families (84). The fragmentation patterns obtained with Xba I initially defined four allelic forms of the CYP2D6 gene, represented by fragments of 29-kb, 44-kb, 11.5-kb, or 16 + 9-kb length, respectively (84, 85). However, only the alleles represented by 44-kb and 11.5-kb fragments were clearly associated with the PM phenotype, thereby accounting for about one half the alleles in the PM group. The remaining half was of the noninformative 29-kb type, which was also the most frequent haplotype in EMs and thus represented the major polymorphic allele (84). The 16 + 9-kb pattern was later also shown to be associated with the PM phenotype (85).
Null alleles Different approaches were taken in several parallel investigations to uncover primary mutations at the DNA level that could explain the PM phenotype (80, 82, 86, 87). By complete sequence analysis of a CYP2D6 allele (44M) isolated from a PM individual characterized as 44-kb/11.5-kb by Xba I RFLP analysis, several mutations were identified in introns and in exons, four of which cause amino acid substitutions (82). One intronic mutation, G1934A, appeared to be the most consequential difference to the wild-type gene in that it affected the consensus acceptor splice site of the third intron. The mechanism proposed for this mutation is outlined in Figure 1 . The G residue within the consensus AG dinucleotide of the 3 acceptor splice site of the normal gene is changed into an A in the mutant allele. As the first exon residue is a G, a new consensus site forms one base downstream, thereby predicting an mRNA with a single base deletion to be the spliced gene product (82). Indeed, variant cDNAs with this deletion were isolated from libraries prepared from low in vitro activity livers (73, 87) . At the protein level, this mechanism predicts premature translation termination to occur at codon 182 (Figure 1) , thus explaining the absence of immunoreactive P450 protein and enzyme activity in PMs homozygous for this mutant allele.
The major polymorphic allele, characterized as a 29-kb Xba I fragment (84), was studied by Kagimoto et al (86) seven mutations found in the sequenced areas were the same as those of the 44M allele and included the G1934A transition (86). COS cell expression of chimeric CYP2D6 genes and mutant cDNAs that contain individual and groups of mutations by Kagimoto et al (86) demonstrated that the G1934A mutation completely abolishes expression of protein and activity. In further agreement with the mechanistic model, mutant CYP2D6 mRNA observed in transfected COS cells had the same size as wild-type mRNA (86). Diagnostic DNA tests then confirmed the high frequency of this mutation among PM individuals (10, (88) (89) (90) (91) .
The other mutations present in the "B-type" alleles do not severely affect protein expression and activity, with the exception of C188T (P34S), which dramatically decreased enzyme activity but not protein expression in transfected COS cells (86). This mutation, as well as a mutation in exon 9 (4268), is also present in several functional alleles (Figure 2 ) and is discussed separately below.
According to a recently proposed CYP2D6 nomenclature system, alleles with multiple mutations are grouped according to common detrimental mutations (92) . Group * 4 comprises all alleles with the G1934A mutation, to which the 29-B ( * 4A) and 29-B ( * 4B), as well as the 44M alleles ( * 4A) belong (92) (Figure 2) .
The second most frequent nonfunctional or null allele in whites is represented by the 11.5-kb Xba I fragment, which was shown to be the result of a large deletion mutation at the CYP2D locus, designated D-allele (80). The structure of this allele was analyzed in genomic clones from a PM individual homozygous for the XbaI 11.5-kb haplotype and was shown to comprise the pseudogenes CYP2D8P and CYP2D7P, whereas the entire CYP2D6 coding sequence is deleted. Figure 2 summarizes the currently known loss of function mutations, most of which can be detected with simple DNA tests (88, 93, 94) . The more recently reported alleles ( * 6 to * 16) were usually detected in PM individuals who had none of the known mutations of alleles A, B, and D. The two most frequent of these ( * 6 and * 3) also result in premature translation termination because of single base deletions. In contrast, the single mutation of allele * 7 predicts an amino acid substitution, H324P, in exon six (95) . Expression of CYP2D6(324P) in COS cells and in insect cells resulted in comparable amounts of mutant and wild-type protein, but the 324P mutant lacked heme and was enzymatically inactive (96) .
Functional alleles Among EM individuals, the MR for debrisoquine varies up to 1000-fold, from as low as 0.01 up to the antimode of 12.6 for debrisoquine (64, 97) and to a similar extent for other substrates. The terms "intermediate metabolizer" (for MR1-12.6) and "ultrarapid metabolizer" [for MR < 0.1, (64)] have been used to describe these phenotypic subpopulations. Some recently identified mutations can be correlated to increased or decreased metabolic capacity and thus appear to contribute to the extreme variability among EMs.
In two human liver samples with low CYP2D6 enzymatic activity, trace amounts of a cross-reactive protein with slightly higher apparent Mr were detected (74) . Subsequent cDNA cloning revealed a CYP2D6-C variant ( * 9) with a deleted codon 281, coding for lysine (98) . The kinetic parameters determined with several substrates for the mutant enzyme expressed by recombinant vaccinia virus in HepG2 cells were comparable to those of the wild-type. Based on the in vitro analyses of liver microsomes, it was initially thought that the allele could be associated with the PM phenotype, but a family study with several members of the C/D ( * 5/ * 9) genotype then allowed the correlation of this allele to intermediate debrisoquine MRs (99) . The overall C-allele frequency in whites is about 1% (97) . Interestingly, however, a higher frequency of this mutation was reported in Spain (100).
The C188T mutation, which causes a Pro to Ser amino acid change at position 34, was first identified as one of several amino acid substitutions in the B-type alleles (82, 86) and was shown by expression in COS cells to impair CYP2D6 enzyme function, but not expression, dramatically (86). Because of this effect, alleles with this mutation but absent detrimental G1934A transition, as first observed in Asian populations and termed J (for Japanese) or Ch (for Chinese) (83, 101, 136) , are grouped in family * 10 ( Figure 2 ). In whites, these alleles are much less frequent than in Asians, but may contribute to the intermediate metabolizer phenotype, as the presence of this mutation was correlated to higher MR of EMs in several studies (83, 101, 102, 136). As noted earlier (82), Pro34 is part of a proline-rich region that is highly conserved among microsomal P450s and may function as a hinge between the hydrophobic membrane anchor and the globular heme-binding portion of the enzyme. Enzymatic activity of COS cell-expressed P34S mutant CYP2D6 was not detectable (86). In combination with a mutation in exon 9 (allele * 10; Figure 2) , it was estimated to be about 5% of the wild-type activity (83). Nevertheless, individuals who have a combined genotype of one * 10 and one nonfunctional allele are always EMs, which indicates that the low amounts of functional enzyme produced by * 10 still provide sufficient metabolic capacity to cause metabolic ratios within the EM phenotype range. At the opposite side of the spectrum of EMs, the "ultrarapid metabolizer phenotype" was also shown to have a genetic basis. It was first observed in a clinical setting in which two patients required antidepressants at unusually high doses ("megaprescribing") to attain therapeutic plasma concentrations (64) . Both patients were subsequently shown to carry one normal and one novel allele characterized by a 42-kb Xba I fragment, which was distinct from the 44-kb haplotype (64). The extremely rapid metabolism in the two patients was suggested to be the consequence of a gene duplication, which led to two functional copies of CYP2D6 * 2 on the 42-kb fragment, thus causing more enzyme to be expressed (64, 97, 103) . In another family with ultrarapid metabolism of debrisoquine in three members (MR < 0.02), molecular analysis demonstrated dominant inheritance of a 13-fold amplified CYP2D6 * 2 gene from the father to two children (103) . The mechanism of this excessive gene amplification remains speculative and restricted to a single observation, whereas the duplicated allele (CYP2D6 * 2 × 2) was shown to occur with allele frequencies of ∼3.5% in Spanish (104) and ∼1% in Swedish populations, where alleles with triplicated CYP2D6 * 2 were also observed (97) . As much as 13% of an Ethiopian population seemed to carry this gene duplication (105) .
The implication of these findings is that each of the multiple CYP2D6 * 2 copies on the variant amplified alleles is expressed and contributes to expression of a functional protein. Although it was not explicitly shown that each of the multiple copies represents a complete functional gene, the inverse correlation found between the number of copies and the MR for debrisoquine strongly suggests such a mechanism (97, 103) .
Multiple copies and amplification of CYP2D6 apparently involves only the variant CYP2D6 * 2, which is distinct from the wild-type gene (79) at several positions, including a gene conversion with CYP2D7 in the first intron and two point mutations that cause amino acid substitutions R296C and S486T (103) . Being present also in a significant proportion of the genes of the common 29-kb haplotype, it represents the second most frequent functional allele in whites, with an overall frequency of approximately 30% (103, 106) . Correlation studies suggest that this variant codes for a protein with normal function, although position 296 maps to a putative substrate recognition sequence of cytochrome P450.
Interethnic Variability and Evolution
As recently reviewed (6, 9), significant ethnic differences exist in the frequency of the PM phenotype, which appears to be rare (1% to 2%) in most populations with the exception of Caucasians (5% to 10%). Interethnic variability of CYP2D6 alleles is less completely studied than the NAT2 polymorphism, but the existing data allow some conclusions on the origin of the most common alleles (Table 4) .
The most extreme variabilities are observed for the two allele families, CYP2D6 * 4 and * 10 ( Figure 2) . The practical absence of the common "white" B-allele from East Asian populations explains the very low prevalence of the PM trait in the latter. A similarly low frequency of this allele was described for two African populations (105, 107) . In most African population studies, PM frequencies were also found to be low, although dissociations have been observed for some probe drugs (6, 9). A possible explanation for these findings is that the B-allele appeared relatively recently in Caucasoids after their separation from Asian/Amerindian groups about 35,000 years ago (58, 107) . The intermediate frequency of * 4 alleles in American blacks is most likely caused by penetrance of Caucasian-derived genes (6). However, a high frequency (17%) was observed in an Amerindian tribes by Jorge et al (108) , an observation that challenges the above hypothesis. The * 3 allele (A-mutation) also appears to be rare except in whites, whereas the deletion-allele, CYP2D6
* 5, occurs with comparable frequency in most populations.
Another major interethnic difference is a shift in the metabolic ratio distribution to higher values in Chinese populations as compared with whites (9). The molecular basis for this phenotypic difference is a very high prevalence in Asians of * 10 alleles with lower enzyme activity due to the C188T (P34S) mutation. Its frequency in whites may have been overestimated initially, as it appears to be rather rare according to recent data (91).
The two major functional * 1 and * 2 alleles appear to be frequent throughout all populations, but one should keep in mind that the frequencies for these alleles are determined by the absence of other mutations. Therefore, undiscovered mutations may change the picture considerably in the future. Compared with whites, a considerably higher incidence of gene duplication and amplification alleles was reported for Ethiopians (105) . The authors discussed the interesting possibility that duplicated and amplified L-alleles (CYP2D6 * 2 × N) may have originated in Africa and transmitted to whites rather recently during the immigration of Arabs into Spain, where a higher frequency is observed than in the rest of Europe (104) . There are no data yet on CYP2D6 alleles in Pacific populations.
THE MEPHENYTOIN POLYMORPHISM
Discovery and Clinical Relevance
A genetic polymorphism of another cytochrome P450 isozyme was revealed by the discovery of deficient 4 -hydroxylation of mephenytoin (3-methyl-5-phenyl-5 ethylhydantoin; Mesantoin), a now rarely used anticonvulsant drug (109, 110) . The deficiency is restricted to one of the two major metabolic pathways of mephenytoin disposition, namely stereoselective hydroxylation of S-mephenytoin in the p-phenyl position to 4 -OH-mephenytoin. The other main reaction, N-demethylation of R-mephenytoin to 5-phenyl-5-ethylhydantoin (PEH; Nirvanol) remains unaffected. This deficiency is inherited as an autosomal recessive trait (111, 112) and occurs with a frequency of 2.5 to 6% in whites, but with a much higher frequency in Japanese (18 to 23%) and Chinese (15 to 17%) individuals (6, 113). Recent reviews of this polymorphism have been published (6, 113, 114) . Individuals who have the PM phenotype are predisposed to have the central adverse effects of mephenytoin, eg., sedation after administration of a single dose of 100 mg for phenotyping purposes (115, 116) . Additional substrates for the enzyme metabolizing S-mephenytoin to 4 -OH-mephenytoin have been tentatively identified by in vitro inhibition studies and some of these have been confirmed by cosegregation in populations. Thus, the metabolism of the N-demethylated metabolite of mephenytoin (nirvanol), mephobarbital, and hexobarbital, the side-chain oxidation of propanolol, the demethylation of imipramin, and the metabolism of diazepam and desmethyldiazepam cosegregate with the 2 -hydroxylation of S-mephenytoin (6, 113, 114) . More recent studies also suggest that the metabolism of the antidepressant citalopram, the proton-pump inhibitor omeprazol (117) , and probably the related drugs pantoprazole and lansoprazole (UA Meyer, unpublished data), as well as the antimalarial prodrugs proguanyl and chlorproguanyl (118) , cosegregate with polymorphic mephenytoin metabolism. The clinical consequences of impaired mephenytoin hydroxylation have not been studied in detail. There is some evidence that the frequency of adverse effects of mephenytoin, mephobarbital, and hexobarbital may be higher in poor metabolizers of mephenytoin (115, 116) . Of potential significance would be a decreased efficacy of prophylaxis for chloroquine-resistant P. falciparum malaria in PMs because of the decreased formation of the active antiplasmodial metabolite cycloguanil or chlorocycloguanil. Initial studies in Tanzania, however, did not support such a relationship (119). May et al (120) have described an association of the PM phenotype with scleroderma, particularly when it occurs in combination with slow dapsone hydroxylation.
Molecular Mechanism
STUDIES IN HUMAN LIVER Initial studies in microsomes of liver biopsy specimens from EM and PM individuals suggested the deficiency of a specific P450 isozyme (121) . Studies in several laboratories during the next few years, however, failed to identify unequivocally the gene and the enzyme affected by this polymorphism. Proteins were purified from human liver by Gut et al (122) and Shimada et al (123) by monitoring S-mephenytoin 4 hydroxylation activity. Antibodies against the purified fractions inhibited S-mephenytoin 4 -hydroxylation, but there was no correlation between immunochemically recognized levels of these proteins and catalytic activity (124, 125) . The issue has now been resolved in that a protein with the N-terminus of CYP2C19, identified by cloning studies (126) , was purified by Wrighton et al (127) . Immunoblots of this protein correlated with S-mephenytoin 4 -hydroxylase activity. These data were confirmed by Goldstein et al (128) by expression of a CYP2C19 cDNA in yeast and refuted previous assumptions that variants of CYP2C9 may contribute significantly to hepatic S-mephenytoin 4 -hydroxylase activity. CYP2C19 appears to be virtually absent on immunoblots of liver microsomes of PMs of mephenytoin (129) .
CYP2C GENES At least seven genes or pseudogenes of the CYP2C subfamily appear to be localized on chromosome 10 (124, 130) . The complete CYP2C18 gene and part of the CYP2C9 gene have been isolated and both are ∼55 kb in size and have nine exons, as have other genes of family 2 (131). The CYP2C19 gene has not been studied so far, but it is closely related to other genes of the 2C subfamily, e.g. CYP2C9, with 95% similarity in the upstream region and in several exons (114) . According to recent nomenclature concepts, the wild-type CYP2C19 gene may also be designated as CYP2C19 * 1.
ALLELES OF CYP2C19
Reverse transcription and amplification of mRNA from liver samples with low microsomal S-mephenytoin 4 -hydroxylase activity revealed a 2C19 cDNA fragment with a 40-bp deletion at the beginning of exon 5, which included a SmaI restriction site. This results in the deletion of 13 amino acids (215-227) and shifts the reading frame, thereby producing a stop codon 20 amino acids downstream and consequently a truncated protein (234 amino acids), which would be devoid of a heme binding site and therefore be inactive. Sequencing of amplified genomic DNA fragments from PM livers revealed a G to A substitution in the coding sequence of exon 5 that corresponded to bp 681 of the cDNA. This mutation, designated CYP2C19m1 (or CYP2C19 * 2) creates an aberrant splice site that is apparently preferred exclusively over the normal splice site. The abolition of a SmaI site by this mutation led to the development of a convenient genotyping test. This mutation accounted for 75% and 83% of the defective allele in a small sample of Japanese and white PM individuals, respectively (129) . A second mutation, defined as CYP2C19m2 (CYP2C19 * 3), has recently been discovered in DNA of a Japanese PM who did not have the m1 mutation. CYP2C19m2 involves a G → A transition at bp 636 in exon 4, which also creates a premature stop codon and destroys a BamHI restriction site. This change would result in a truncated 211 amino acid polypeptide (132) . A PCR test for this mutation revealed that CYP2C19m2 accounts for the remaining defective alleles in Japanese or Chinese PMs. PCR-based tests for the CYP2C19m1 and m2 mutations have been described (129, 132) and have been evaluated in population and family studies to be of high sensitivity and selectivity. However, whereas virtually all PMs in Japan had the genotypes m1/m1, m1/m2, or m2/m2, the m2 mutation appears to be exceedingly rare in whites.
A large family study (43 relatives of families of 11 PM probands) in Denmark (133) revealed only one m2 mutation, and random testing of 800 alleles from whites revealed no m2 alleles (114) . In conclusion, the two CYP2C19 mutations m1 and m2 explain virtually all PMs in Japanese and Chinese populations, but additional mutations of CYP2C19 must exist in whites.
Interethnic Variability and Evolution
The ethnic and geographic distribution of the mephenytoin polymorphism has been less well studied than that of the acetylation and debrisoquine polymorphism. A summary of 18 phenotyping studies that has recently been published (134) includes Saudi Arabians, Filipinos, and Indians. An interesting relationship between longitude and the frequency of PMs was observed, which suggests a cline containing a step that occurs between Riyadh and Bombay. The Saudi population resembled Europeans in the frequency of PMs for mephenytoin but was similar to Asians in the frequency of PMs for debrisoquine.
DIRECTIONS FOR FUTURE RESEARCH
The initial observations of unexpected toxicity and the large number of compounds metabolized by NAT2, CYP2D6, and CYP2C19 have resulted in a considerable research effort to understand the molecular mechanisms of these polymorphisms. For example, the unraveling of the complex and highly polymorphic CYP2D gene cluster on chromosome 22 has thus resulted in the characterization of a total of 48 mutations and 53 alleles of the CYP2D6 locus alone (91) . In contrast to the detailed knowledge of molecular mechanisms, however, the clinical relevance of these polymorphisms is poorly documented and is deduced largely from anecdotal reports and epidemiologic studies in small numbers of patients. There is an obvious discrepancy between detailed molecular information and only rudimentary clinical evaluation of the consequences of these polymorphisms. The availability of genotyping tests should help design prospective clinical studies of adverse drug reactions and drug toxicity and should ultimately serve to help in the adjustment of drug doses to individual metabolic capacity.
The associations of these polymorphisms with individual risk to develop certain diseases suggest that the polymorphic enzymes may activate or inactivate environmental carcinogens, other xenobiotics, or endobiotics. With the exception of amine carcinogens as substrates for acetyltransferases, however, the search for chemical carcinogens that may be activated or inactivated by CYP2D6 or CYP2C19 has not been successful. Finally, the potential role of the discussed enzymes in the metabolism of endogenous substances, for instance endogenous codeine and morphine by CYP2D6 (135) or hormones and neurotransmitters, as inferred from indirect observations, has not been evaluated (62) .
ACKNOWLEDGMENTS
We thank Drs. F. Broly, J. Agundez, and M. Ingelman-Sundberg for sending us data and copies of articles that were in press. The research in the laboratory of UAM is supported by the Swiss National Research Foundation. Ulrich M. Zanger is supported by the Robert Bosch Foundation, Stuttgart, Germany.
Visit the Annual Reviews home page at http://www.annurev.org. 
Literature Cited
